BetterLife's Preclinical Studies Of BETR-001 For Depression Gets Additional Sponsorship By Mitacs

Biotech psychedelics company BetterLife Pharma Inc. (OTCQB: BETRF )  in collaboration with the Carleton University Dept. of Neuroscience  has received funding from the Mitacs Accelerate Program for research into the antidepressant effects and action mechanism of BETR-001 in preclinical models of depression. A Canadian non-profit organization, Mitacs is experienced in designing and delivering research and training programs. They network and partner with governments, the private sector, other non-profit ... Full story available on Benzinga.com